161869-03-0

Basic information

• Product Name: MOC-DIP
• Synonyms: MOC-DIP;(S)-2-(METHOXYCARBONYL)-3,3-DIPHENYLPROPANOIC ACID
• CAS NO: 161869-03-0
• Molecular Formula: C₁₇H₁₇NO₄
• Molecular Weight: 284.30654
• Mol File: 161869-03-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: MOC-DIP(CAS DataBase Reference)
• NIST Chemistry Reference: MOC-DIP(161869-03-0)
• EPA Substance Registry System: MOC-DIP(161869-03-0)

Safety Data

• Hazardous Substances Data: 161869-03-0(Hazardous Substances Data)

Upstream product

• 34973-13-2 1-[(methoxycarbonyl)oxy]pyrrolidine-2,5-dione 
• 149597-92-2 (S)-β,β-diphenyl-α-alanine 
• 79-22-1 methyl chloroformate 
• 138662-62-1 (2S)-3,3-Diphenylalanine hydrochloride 

Downstream Products

• 612547-56-5 (S)-(1-{(S)-5-[(4-cyanobenzenesulfonyl)isobutylamino]-6-hydroxyhexylcarbamoyl}-2,2-diphenylethyl)carbamic acid methyl ester 
• 874339-65-8 (1S,5S)-(1-{5-[(4-amino-benzenesulfonyl)-isobutyl-amino]-6-phosphonooxy-hexylcarbamoyl}-2,2-diphenyl-ethyl)-carbamic acid methyl ester 
• 874339-76-1 (1S,5S)-{1-[5-[(4-amino-benzenesulfonyl)-isobutyl-amino]-6-(diethoxy-phosphoryloxy)-hexylcarbamoyl]-2,2-diphenyl-ethyl}-carbamic acid methyl ester 
• 938193-51-2 2,5-dioxopyrrolidin-1-yl N-(methoxycarbonyl)-β-phenyl-L-phenylalaninate 
• 1374138-30-3 methyl N6-[N-(methoxycarbonyl)-β-phenyl-L-phenylalanyl]-N2,N2-bis(tert-butoxycarbonyl)-5,5-difluoro-L-lysinate 
• 1374041-10-7 N-{2-[(3S)-3-amino-4-{[tert-butyl(diphenyl)silyl]oxy}butyl]phenyl}-Nα-(methoxycarbonyl)-β-phenyl-L-phenylalaninamide 
• 1374041-11-8 N-{2-[(3S)-4-{[tert-butyl(diphenyl)silyl]oxy}-3-{[(4-nitrophenyl)sulfonyl]amino}butyl]phenyl}-Nα-(methoxycarbonyl)-β-phenyl-L-phenylalaninamide 
• 1374041-12-9 N-{2-[(3S)-4-{[tert-butyl(diphenyl)silyl]oxy}-3-{(3-methylbutyl)[(4-nitrophenyl)sulfonyl]amino}butyl]phenyl}-Nα-(methoxycarbonyl)-β-phenyl-L-phenylalaninamide 
• 1374041-13-0 N-{2-[(3S)-4-hydroxy-3-{(3-methylbutyl)[(4-nitrophenyl)sulfonyl]amino}butyl]phenyl}-Nα-(methoxycarbonyl)-β-phenyl-L-phenylalaninamide 
• 1374040-71-7 N-{2-[(3S)-3-{[(4-aminophenyl)sulfonyl](3-methylbutyl)amino}-4-hydroxybutyl]phenyl}-Nα-(methoxycarbonyl)-β-phenyl-L-phenylalaninamide 
• 1431877-96-1 N-[(1S)-1-{5-[(1R)-1-amino-2-{[tert-butyl(dimethyl)silyl]oxy}ethyl]thiophen-2-yl}-2,2,2-trifluoroethyl]-Nα-(methoxycarbonyl)-β-phenyl-L-phenylalaninamide 
• 612547-11-2 (1S,5S)-(1-{5-[(4-amino-benzenesulfonyl)-isobutyl-amino]-6-hydroxy-hexylcarbamoyl}-2,2-diphenyl-ethyl)-carbamic acid methyl ester 

Relevant articles and documents

HIV PROTEASE INHIBITORS

Compounds of Formula I are disclosed: wherein A, R1, R2, R3, R4A, R4B, R5, R6 and R7 are defined herein. The compounds encompassed by Formula I include compounds which

SULFONAMIDES AS HIV PROTEASE INHIBITORS

Compounds of Formula I are disclosed: wherein L, A, R1, R2, R3A, R3B, R4A, R4B, R5, R6 and R7 are defined herein. The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HW protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines

Epsilon substituted lysinol derivatives as HIV-1 protease inhibitors

A series of HIV-1 protease inhibitors containing an epsilon substituted lysinol backbone was synthesized. Two novel synthetic routes using N-boc-l-glutamic acid alpha-benzyl ester and 2,6-diaminopimelic acid were developed. Incorporation of this epsilon s

LYSINE-BASED PRODRUGS OF ASPARTYL PROTEASE INHIBITORS AND PROCESSES FOR THEIR PREPARATION

The present invention provides processes for synthesizing lysine based compounds of the Formula (I); wherein R1 may be, for example, (HO)2P(O)-, (NaO)2P(O)-, wherein X may be, for example, NH2, Y may be H, F, Cl, or Br, and wherein n, X', Y', R2, R3, R4, R5 and R6 are as defined herein.

LYSINE BASED COMPOUNDS

The present invention provides lysine based compounds of the formula (I); and when the compound of formula (I) comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein Rl may be, for example, (HO)2P(O)-, (NaO)2P(O)-, alkyl-CO- or cycloalkyl-CO-, wherein X may be, for example, F, Cl, and Br, and wherein R2 and R3 are as defined herein. These lysine based compounds have a physiologically cleavable unit, namely R1 , whereby upon cleavage of the unit, an HIV aspartyl protease inhibitor is released,

METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS

The present invention provides methods for improving the pharmacokinetics of protease inhibitors and protease inhibitor precursors and pharmaceutical composition comprising protease inhibitors or protease inhibitor precursors of formula I and a cytochrome P450 monooxigenase inhibitor; Formula (I) when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein R1 may be, for example, (HO)2P(O)-, (NaO)2P(O)-, alkyl- CO- or cycloalkyl-CO-, wherein X may be, for example, F, CI, and Br, and wherein R2 and R3 are as defined herein.

Lysine sulfonamides as novel HIV-protease inhibitors: Nε-Acyl aromatic α-amino acids

A series of lysine sulfonamide analogues bearing Nε-acyl aromatic amino acids were synthesized using an efficient synthetic route. Evaluation of these novel protease inhibitors revealed compounds with high potency against wild-type and multiple-protease inhibitor-resistant HIV viruses.

Lysine based compounds

The present invention provides lysine based compounds of the formula; and when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein R1 may be, for example, (HO)2P(O)—, (NaO)2P(O)—, alkyl-CO— or cycloalkyl-CO—, wherein X may be, for example, F, Cl, and Br, and wherein R2 and R3 are as defined herein.

Aromatic derivatives as HIV aspartyl protease inhibitors

The present invention provides HIV aspartyl protease inhibitors of the formula; and when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein n is 3 or 4, wherein R1may be, for example,

Pictet-Spengler cyclization of 3,3-diphenylalanine (DIP) (III), synthesis of optically pure 1,2,3,4-tetrahydro-4-phenyl-3-isoquinolinecarboxylic acids, novel α-amino acids for peptides of biological interest

All four isomers of 1,2,3,4-tetrahydro-4-phenyl-3-isoquinolinecarboxylic acid have been synthesized in high optical purity for the synthesis of peptides of biological interest.